Business Wire

RELIEF THERAPEUTICS Holding SA Announces an Out-Licensing Agreement with H&H Group

Del

RELIEF THERAPEUTICS Holding SA (“Relief”, “the Company”) announces that it has concluded a licensing and co-development agreement (the “Agreement”) with Health and Happiness (H&H) Hong Kong Limited (“H&H”), part of H&H Group to develop products which are derived from whey and/or no-fat milk and have the potential to prevent allergies. The Agreement will follow a four-year development plan including pre-clinical and clinical milestones with the goal of reducing allergenicity or even preventing food (particularly milk) allergy in humans. The product(s) under development are based on the technology discovered by the French company Genclis SA (“Genclis”) that has established the role and consequences of Transcription Infidelity (TI) on allergy. This series of discoveries are the basis for their patent application referred to as the Molecular Origin of Allergy (WO 2017/158202) on which Relief has acquired in April 2018 a license for the development and commercialization of hypoallergenic milk produced without hydrolysis.

The global allergy market that includes diagnostic and therapeutic, is currently growing at a 5.5% CAGR per year and is estimated to reach $42.8 billion by 2022 (Grand View Research, January 2016).

The Agreement includes upfront and milestone payments as well as royalties on any products generated via the collaboration that, as contractually agreed, are distributed across the entire duration of the program. In addition, H&H will fund development to be conducted at Genclis as well as at H&H premises. Details of the overall financial contribution are not disclosed.

Patrice Malard, Chief Technology Officer of H&H declares: “The H&H group ambitions to become a global leader in advanced baby nutrition and care, this Agreement is an important step for our company to reach and serve in a disruptive manner this current $6 billion-hypoallergenic milk infant market. We have been positively impressed by the potential of the technology developed at Genclis and we are excited to work with both Relief and Genclis to translate this technology into novel commercial products.

Bernard Bihain, Chief Executive Officer of Genclis adds: “We are thrilled to take part in this ambitious program relying on a disruptive basic science finding to obtain industrial application that will greatly benefit the general health and can provide powerful innovative solution for children of allergic parents.

Gaël Hédou, Chief Executive Officer of Relief concludes by saying: “We are pleased to see that Relief could convey to H&H our appreciation of the groundbreaking and disruptive nature of Genclis’ discoveries. Given the fluidity and speed of the interaction that we experienced during the course of the discussions between the different stakeholders to reach this Agreement, we are confident that this collaboration will be efficient and rapidly productive

About H&H

Health and Happiness (H&H) Hong Kong Limited is a subsidiary of Health and Happiness (H&H) International Holdings Limited which is listed on the Main Board of the Stock Exchange of Hong Kong and part of H&H Group. H&H Group was established in 1999, it operates through two core business segments - Baby Nutrition and Care and Adult Nutrition and Care. The Baby Nutrition and Care segment engages in production of infant formulas for children under seven years old and milk formulas for expectant and nursing mothers, production of probiotic supplements, and production of baby care products. The Adult Nutrition and Care Products segment is engaged in the production of vitamins, health supplements, skin care and sports nutrition products for adults. H&H Group currently owns four international brands: Biostime ® : global leader in premium infant nutrition; Swisse ®: Australia’s leading natural health brand; Healthy Times ®: a favorite organic baby food brand in the US since 1980’s; Dodie ®: French heritage brand since 1957 in baby bottles and accessories. H&H Group is a premium nutrition and wellness provider for the entire family, it aspires to make people healthier and happier.

About Relief Therapeutics Holding SA

RELIEF THERAPEUTICS Holding AG is a clinical-stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two first candidates are Aviptadil for the treatment of sarcoidosis (to enter Phase III) and low dose interleukin-6 (Atexakin alfa) for the treatment of peripheral neuropathy (to enter Phase II). Aviptadil development in sarcoidosis addresses the orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, The current priority indication for Atexakin is to alleviate peripheral diabetic neuropathy, a market that is estimated to reach $4.1 billion in 2019 (source Datamonitor). In addition to these initial drug candidates, Relief has initiate a strategic collaboration with Genclis in April 2018 in order to co-develop and commercialize products arising from their disruptive technology.

About Genclis SA

Genclis is a privately-held biotechnology company incorporated in 2004 in Vandœuvre-lès-Nancy, France, that discovered a unique biological mechanism referred to as Transcription Infidelity (TI). TI produces RNA transcripts that differ from their originating DNA sequence. This mechanism explains the nonrandom occurrence of RNA to DNA divergences (RDD) that lead to translated proteins with sequences diverging from the canonical form. Genclis applies its artificial intelligence platform to extract, from large Genomic data sets, these low-intensity signals. Genclis has shown in both humans and animal models that specific RDD events shape selectively the repertoire of natural immunoglobulins and contribute to both allergy and other immunological disorders. Genclis has developed a diversified pipeline of disruptive diagnostic and therapeutic solutions that have and are completing pre-clinical evaluation. Genclis revenues grew >500 % to €2.2 million in fiscal year 2017 missing breakeven by less than 10 %. Genclis’ objectives for 2018 are to further expand commercial activities in both human and veterinary medicine as well as in the food industry to reach profitability, while relentlessly pursuing developments of several other novel disruptive pre-clinical assets.

About Transcription Infidelity

Transcription Infidelity (TI) is a newly discovered ubiquitous epigenetic mechanism that increases RNA-DNA sequence divergences (RDD). TI was initially described and patented by Genclis1 and has since been confirmed by several independent academic teams2. TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity3. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.

1 Brulliard et al., 2007. PNAS, 104 (18): 7522–27 and “Transcription Infidelity, detection and uses thereof”, EP2046986, US8288091.
2 Ju et al., 2011. Nature Genetics 43 (8): 745–52; Li et al., 2011. Science, 333 (6038): 53–58; Peng et al., 2012. Nat Biotechnol 30: 253–60, Reid-Bayliss and Loeb, 2017. PNAS 114 (35): 9415.
3 Genclis patent: “Molecular origin of allergy“, EP16305297, WO2017158202A1.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Geneva, Switzerland.

For further information, please visit the Relief website at www.relieftherapeutics.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Contact information

RELIEF THERAPEUTICS Holding SA
Dr. Gael Hédou
gael.hedou@relieftherapeutics.com
tel: +41 79 457 0937

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma20.9.2018 17:21Pressemelding

Pierre Fabre today announced that the European Commission (EC) has granted marketing authorisation for the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.1,2 The EC decision is applicable to all 28 European Union (EU) member states plus Liechtenstein, Iceland and Norway. "We are extremely pleased that European patients with advanced BRAF-mutant melanoma will now have the combination of BRAFTOVI and MEKTOVI as a new treatment option”, said Frédéric Duchesne, President & CEO of the Pierre Fabre Pharmaceuticals Division. “All of us at Pierre Fabre are driven to make a real difference for patients. Bringing more than 30 years of oncology experience and our heritage in dermatology to our partnership with Array BioPharma, we have been able to harness our expertise in order to help men and women living with this devastating disease. Today’s

Clothesource Report Shows Retail Sales Aren’t Falling or Moving Online: Management’s Let Itself Get Misguided20.9.2018 17:19Pressemelding

According to a new Clothesource report, “The Emperors’ Clothes” retail sales aren’t falling, and they’re not leaving physical stores. Both the UK’s Office of National Statistics and the US Bureau of the Census report higher retail sales than ever – with sales in physical stores still growing every year. Retailers just need to rely on their own customer understanding, recapture their self-confidence, and rediscover their traditional frugality. Among recent front-page stories have been Sears in the US hinting it’s about to go under and profits at Britain’s John Lewis falling 99%. But the well run clothing retailers are prospering. Primark goes from strength to strength: the biggest clothing specialists on either side of the Atlantic (Inditex and TJX) have just upped their sales and profit forecasts. So it’s not about consumer purchasing: The main problem lies with management, says Clothesource CEO Mike Flanagan in a new report “The Emperors’ Clothes”. They’ve lost touch with their custom

BCW Names Latin America Market Leaders20.9.2018 16:23Pressemelding

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced the appointment of market leaders in Latin America who will be responsible for business growth, client satisfaction and talent development. All market leaders report to Francisco Carvalho, President, Latin America, BCW. “BCW has a dominant presence in Latin America, thanks to Burson-Marsteller’s 40-year-history and expansive footprint across the region and Cohn & Wolfe’s strength in Brazil and Mexico,” said Carvalho. “This team has unmatched market knowledge, strong client relationships and deep commitment to talent, all of which is critical for our continued success in the region. Those strengths, together with our industry-leading expertise in delivering digitally driven integrated communications programs, make BCW a powerful partner for our clients.” All of BCW’s Latin America market leaders have been drawn from the legacy Burson-Marsteller organization and had been leading their respective markets, e

NavVis Achieves Breakthough 6D SLAM Indoor LiDAR Mapping With Velodyne’s 3D LiDAR Sensor20.9.2018 14:43Pressemelding

On April 18th, 2018, NavVis released their M6, a fully-integrated, cart-based system designed for large-scale indoor mapping. The M6 utilizes VLP-16 sensors by Velodyne LiDAR, Inc., which allows it to produce a 3D map of the surrounding environment. Six cameras capture 360° immersive imagery and photorealistic point-clouds, resulting in high-resolution mapped images. NavVis developed this product in response to their customers’ request for a more versatile and sophisticated system which could be used effectively with uneven terrain. In addition to AEC professionals, construction companies and manufacturers can also draw benefits from the higher data quality provided by this enhanced innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005560/en/ NavVis M6 is a fully-integrated, cart-based system designed for large-scale indoor mapping. (Photo: Business Wire) The M6 was developed by NavVis after customers requeste

Steve Bannon’s New Documentary Film Trump @War Launches Free Online Access20.9.2018 14:34Pressemelding

Trump @War in conjunction with its online distribution partner, The Western Journal, is pleased to announce that the full length HD feature film Trump @War is free and available to viewers worldwide at Trumpmovienow.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005553/en/ Watch free full-length feature film: trumpmovienow.com (Photo: Business Wire) “The Western Journal does great work and we are happy they are partnering with us,” stated Stephen K. Bannon. “It’s a film that every American, regardless of political belief, should watch. It’s a historic time for our country, and no one should be sitting on the sidelines during the upcoming elections.” Directed by Bannon and produced by Dan Fleuette, Trump @War is a retelling of the most significant election campaign in modern U.S. history and a look forward to the high-stakes midterm election in November 2018, which will cement President Trump’s legacy. “Steve Banno

GTIS Partners Grabs Top Spots in Prestigious GRESB Sustainability Ranking20.9.2018 14:24Pressemelding

GTIS Partners LP (“GTIS”), a real assets investment firm headquartered in New York City, with offices in São Paulo, Los Angeles, San Francisco, Atlanta, Paris and Munich, today announced that the GTIS Brazil Real Estate Fund (“GTIS Brazil Real Estate Fund I”) has been recognized as 2018’s most sustainable private equity real estate investment fund in South America by the Global Real Estate Sustainability Benchmark (GRESB). This is the fourth year running the fund has clinched the top ranking. GTIS Brazil Real Estate Funds II and III took second- and third-place honors, respectively, matching the funds’ 2017 survey rankings. “Our across-the-board top-place rankings are a testament to the day-in, day-out efforts of the entire GTIS Brazil team, who’ve incorporated environmental, social and governance principles into their investment and management practices,” said Josh Pristaw, Senior Managing Director, Head of Capital Markets and Co-head of Brazil at GTIS Partners. “What we’re most proud